• 1
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458.
  • 2
    Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al.; Austrian Hepatitis Study Group. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virological response. Gastroenterology 2010; 138: 503-512.
  • 3
    Zeuzem S, Bute M, Ferenci P, Sperl J, Hosmans Y, Cinaciara J, et al. Efficiency of 24 weeks treatment with peginterferon alfa-2b plus ribavirin patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
  • 4
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 5
    Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140: 346-355.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
  • 7
    Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja LJ, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serin protease inhibitor in hepatitis C genotype1 patients. Gastroenterology 2004; 127: 1347-1355.
  • 8
    Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-1998.
  • 9
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pols S, Goeser T, et al.; PROVE, 2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 10
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin in chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
  • 11
    Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468.
  • 12
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase 2 trial. Lancet 2010; 376: 705-716.
  • 13
    Poordad F, McCone J,Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 31: 364: 1195-1206.
  • 14
    Jacobson IM, McHutchison JG, Dusheiko G, DiBisceglie AM, Reddy RK, Browej N, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 15
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
  • 16
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 17
    Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 4: 344-350.
  • 18
    Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011: 53: 336-345.
  • 19
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
  • 20
    Zeuzem S, Nelson DR, Andreone P, Ferenci P, Herring R, Jensen DM, et al. Phase IIB study of balapiravir (RG1626; Nucleoside analogue inhibitor of HCV polymerase) plus peginterferon alfa-2a (40KD) and ribavirin for CHC genotype 1: final results. J Hepatol 2010; 52 ( Suppl. 1): S302-S303.
  • 21
    Törner A, Duberg AS, Dickman P, Svensson A. A proposed method to adjust for selection bias in cohort studies. Am J Epidemiol 2010; 171: 602-608.
  • 22
    Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to pegInterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40: 251-260.
  • 23
    Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48: 736-742.
  • 24
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
  • 25
    Berg T, Sarrazin C, Hermann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C and significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609.
  • 26
    Melia MT, Muir AJ, McCone J, Schiffman ML, King JW, Herrine SK, et al. Racial differences in hepatitis C treatment. Hepatology 2011; 54: 70-78.
  • 27
    Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737-745.
  • 28
    Dai CY, Yeh ML, Huang JF, Chuang WL, Yu ML. Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. Hepatology 2011; 53: 1399.
  • 29
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
  • 30
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
  • 31
    Jacobson LM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the Advance Trial. J Hepatol 2011; 54( Suppl. 1): S542: 1369.
  • 32
    Zeuzem S, Foster GR, Fried MW, Hezode C, Hirschfield GM, Nikitin I, et al. The Aspire Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PEGIFN/RBV treatment. J Hepatol 2011; 54( Suppl. 1): S546: 1376.
  • 33
    Aronson A, Jensen D. Distributive justice and the arrival of direct acting antivirals: who should be first in line? Hepatology 2011: 53: 1789-1791.
  • 34
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. New Engl J Med 2011; 364: 2199-2207.
  • 35
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
  • 36
    Hofer H, Gurguta C, Bergholz U, Steindl-Munda P, Ferenci P. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. Wien Klin Wochenschr 2006; 118: 595-600.